预约演示

CureVac, chasing Moderna's mRNA flu vaccine, runs into the same B strain problems

2024-04-04

疫苗临床2期临床3期临床结果信使RNA

“We are confident that planned optimizations will improve performance against these historically challenging influenza strains,” CureVac's chief development officer said.

CureVac and GSK have been racing behind Moderna to try to get the first mRNA flu vaccine to market. But, now,influenzapean partners have come up against the exact same problem as their U.S. competitor when it comes to the "historically challenging" B strains of influenza.

Interim resuGSK from an ongoing phase 2 Modernaf the companies’ seasonalmRNA flu vaccinedate showed that the shot “boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose,” CureVainfluenzad in an April 4 release.

But, while CureVac’s GSK94180-partnered shot was able to beat liseasonal influenzas in triggering an immune response against influenza A strains, the candidate was unable to manage the same feat against strains of influenza B.

Moderna’s fCureVacramGSK94180-partnered problem, with a previous versioflufvaccines. biotech’s mRNA-1010 vaccine failing to minfluenzaon-inferiority threshold for two influenza B strains a year ago. Moderna was latinfluenza Bbring a new formulation into the clinic that overcame this setback.

Moderna wiflunow also work on “targeted optimizations” to improve the vaccine’s protection agaimRNA-1010 vaccine that will be tested in a separate phase 2 study.influenza Moderna

“Immunogenicity for B strains was in line with our expectations also in view of other initial mRNA-based clinical flu development programs,” CureVac Chief Development Officer Myriam Mendila, M.D., said in the release. “We are confident that planned optimizations will improve performance against these historically challenging influenza strains.”

The current phase 2 trial is assessing the vaccine in 480 adults aged 18 to 64 years and another 480 healthy olderfluults aged 65 to 85, with three dose levels across each age group. In the younger group, immune responses were compared to an approved but unnamed “standard dose seasonal vaccine” while in the older group the reinfluenzaere compared to a “high dose seasonal flu vaccine,” according to CureVac.

The company said the shot had an “acceptable safety and tolerability profile” with most of the adverse events reported in the week after dosing being either mild or moderate.seasonal flu vaccine

“The phase 2 interim data show that CureVac’s highly effective and flexible mRNA technology platform puts us on the right track to advance our joint seasonal influenza vaccine program,” Mendila said.

Despite touting the vaccine’s “strong” results against influenza A strains, the ability to fight off all WHO-recommended strains will be key for CureVac. The influenzamends protection against the two A subtypes, H1N1 and H3N2, as well as the influenza B Victoria and Yamagata lineages, be included in annual flu shots.

Even if CureVac and GSK can rapidly improve their vacciinfluenzacacy against those B strains, they will still be trailing Moderna, which bested GSK’s Fluarix in a phase 3 trial that read out in September 2023. Moderna now has an extension of influenzay ongoing in older adults and intends to file for approval this year.

Moderna’s mRNA flu ambitions received a shot in the arm last week when Blackstone Life Sciences agreed to provide “up to” Modernallion to fund the bioFluarixvaccines work, in return for an undisclosed amount ofModernaative” commercial milestone payments and “low-single-digit” royalties on any approved products.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构